Akynzeo 300 mg/0.5 mg hard capsules

DRUG4 trials

Sponsors

K-Group Beta Inc., Fondazione IRCCS Istituto Nazionale Dei Tumori, Karyopharm Therapeutics Inc.

Conditions

Endometrial cancerFallopian TubeHigh-Grade Serous OvarianTreatment naïve patients with MFor Primary Peritoneal Cancerrecurrent or persistent uterine serous carcinoma

Phase 2

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

RecruitingCTIS2022-502983-19-00

K-Group Beta Inc.Fallopian Tube, High-Grade Serous Ovarian, or Primary Peritoneal Cancer

Start: 2025-07-31Target: 137Updated: 2026-01-22

A Phase 2 Open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

CompletedCTIS2023-507324-23-00

K-Group Beta Inc.recurrent or persistent uterine serous carcinoma

Start: 2024-05-22End: 2025-10-23Target: 70Updated: 2024-04-11

Phase 3

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Active, not recruitingCTIS2023-506139-13-00

Karyopharm Therapeutics Inc.Treatment naïve patients with MF

Start: 2024-01-04Target: 195Updated: 2025-10-09

Phase 4

Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study.

RecruitingCTIS2023-504150-35-00

Fondazione IRCCS Istituto Nazionale Dei TumoriEndometrial cancer

Start: 2024-02-21Target: 84Updated: 2025-12-01